Gallbladder Cancer – Pipeline Review, H2 2017 – Research and Markets

Cancer – Pipeline Review, H2 2017”
report has been added to Research
and Markets’

Gallbladder Cancer – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Gallbladder Cancer
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Gallbladder Cancer (Oncology) pipeline guide also reviews of key
players involved in therapeutic development for Gallbladder Cancer and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase II, Phase I and
Preclinical stages are 14, 4 and 2 respectively. Similarly, the
Universities portfolio in Phase I stages comprises 1 molecules,

Gallbladder Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Gallbladder Cancer – Overview
  3. Gallbladder Cancer – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Gallbladder Cancer – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Gallbladder Cancer – Companies Involved in Therapeutics Development
  • 4SC AG
  • Advenchen Laboratories LLC
  • Array BioPharma Inc
  • Aslan Pharmaceuticals Pte Ltd
  • Bayer AG
  • BeiGene Ltd
  • Eli Lilly and Co
  • Halozyme Therapeutics Inc
  • Hutchison MediPharma Ltd
  • Ipsen SA
  • Kringle Pharma Inc
  • Leap Therapeutics Inc
  • MedImmune LLC
  • Molecular Templates Inc
  • Novartis AG
  • NuCana Plc
  • OncoTherapy Science Inc
  • VasGene Therapeutics Inc

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Oncology